Publications by authors named "P M Sandset"
Unhealthy aging poses a global challenge with profound healthcare and socioeconomic implications. Slowing down the aging process offers a promising approach to reduce the burden of a number of age-related diseases, such as dementia, and promoting healthy longevity in the old population. In response to the challenge of the aging population and with a view to the future, Norway and the United Kingdom are fostering collaborations, supported by a "Money Follows Cooperation agreement" between the 2 nations.
View Article and Find Full Text PDFBackground: The procoagulant phenotype in cancer is linked to thrombosis, cancer progression, and immune response. A novel treatment that reduces the risk of both thrombosis and cancer progression without excess bleeding risk remains to be identified.
Objectives: Here, we aimed to broadly investigate the breast tumor coagulome and its relation to prognosis, treatment response to chemotherapy, and the tumor microenvironment.
Aim: An open-label phase 2/3 study of plasminogen, human-tvmh administered intravenously in paediatric and adult subjects with type 1 plasminogen deficiency was conducted. Interim data was previously reported. The final data on 15 subjects who completed the study up to a maximum of 124 weeks are reported here.
View Article and Find Full Text PDFArticle Synopsis
- The development of organoid models, especially for the liver, addresses the limitations of traditional 2D cell culture by creating more physiologically relevant systems that better mimic native tissue.
- The new approach eliminates the need for 2D patterning and extracellular matrices, using small molecules to replicate embryonic liver development, resulting in liver-like organoids with complex cellular structures.
- These liver organoids demonstrate critical functions such as drug metabolism and protein production, and can be transplanted into mice, maintaining their functionality and offering potential for applications in therapy, drug testing, and disease modeling.
Introduction: In a recent interventional study of cancer patients with newly diagnosed venous thrombosis (VT), we found a high risk of arterial thrombotic events (AT) during treatment with therapeutic doses of apixaban.
Methods: Total 298 cancer patients with VT received apixaban as treatment and secondary prophylaxis for up to 36 months. AT was registered as a serious adverse event, and this is a post hoc analysis of risk factors for AT.